Featured Research

from universities, journals, and other organizations

Sciatica Pain Study Seeks Volunteers

Date:
April 4, 2005
Source:
Washington University School Of Medicine
Summary:
Researchers at Washington University School of Medicine in St. Louis are testing the effectiveness of an investigational drug for the treatment of sciatica pain.

March 22, 2005 — Researchers at Washington University School of Medicine in St. Louis are testing the effectiveness of an investigational drug for the treatment of sciatica pain.

Sciatica involves pain in the lower back and hip that radiates down the thigh into the leg. It usually is caused by a combination of compressed nerve roots in the spinal cord and inflammation in the sciatic nerve. It often occurs with inflamed or herniated disks.

Pain from sciatica is called neuropathic pain because it is caused by damage to the nervous system. Many new therapies have been introduced to treat neuropathic pain, but not all patients benefit from existing therapies. This study is recruiting people with sciatica pain due to inflamed nerve roots in the lower back.

"Patients with sciatica often refer to their problem as a shooting pain like electricity down the leg," says anesthesiologist Rahul Rastogi, M.D., principal investigator, who sees patients at the Pain Management Center at Washington University and Barnes-Jewish Hospital. "Sometimes it also can be more of a burning pain or a tingling pain that resembles the feeling people get when their leg 'goes to sleep."

Rastogi and colleagues are studying the ability of the investigational drug REN-1654 to help control or eliminate that pain. The investigational medication is a novel, orally-active, small molecule inhibitor of TNF-alpha, a known proinflammatory cytokine which has been shown to be involved in neuropathology and pain associated with sciatica. REN-1654 is thought to have promise as a treatment for sciatica because it has been shown to interfere with communication between nerve cell receptors that may carry pain messages.

To be eligible for the study, volunteers must be between the ages of 18 and 55 and have leg pain radiating from the lower back to or below the knee that has been diagnosed as pain due to sciatica or to lumbar or lumbosacral radiculopathy. The onset of pain must have occurred two to 12 weeks prior to the initiation of study treatment.

Those who qualify for the study will receive a daily dose of either the study medication or an inactive placebo for three weeks. All participants will have their leg and back pain evaluated at one and three weeks after the start of treatment. Volunteers then will discontinue treatment and remain off medication for three weeks. At the end of those six weeks participants will be evaluated again.

Participation in the study is expected to last for about eight weeks Volunteers will receive free study-related physical exams, laboratory tests and investigational study medication. They will be compensated for time and travel.

The study will require five visits to the Pain Management Center, located in the Center for Advanced Medicine at Washington University and Barnes-Jewish Hospital.

For more information, call study coordinator Patty Suntrup at (314) 747-1709.


Story Source:

The above story is based on materials provided by Washington University School Of Medicine. Note: Materials may be edited for content and length.


Cite This Page:

Washington University School Of Medicine. "Sciatica Pain Study Seeks Volunteers." ScienceDaily. ScienceDaily, 4 April 2005. <www.sciencedaily.com/releases/2005/03/050326003200.htm>.
Washington University School Of Medicine. (2005, April 4). Sciatica Pain Study Seeks Volunteers. ScienceDaily. Retrieved July 30, 2014 from www.sciencedaily.com/releases/2005/03/050326003200.htm
Washington University School Of Medicine. "Sciatica Pain Study Seeks Volunteers." ScienceDaily. www.sciencedaily.com/releases/2005/03/050326003200.htm (accessed July 30, 2014).

Share This




More Health & Medicine News

Wednesday, July 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Concern Grows Over Worsening Ebola Crisis

Concern Grows Over Worsening Ebola Crisis

AFP (July 30, 2014) Pan-African airline ASKY has suspended all flights to and from the capitals of Liberia and Sierra Leone amid the worsening Ebola health crisis, which has so far caused 672 deaths in Guinea, Liberia and Sierra Leone. Duration: 00:43 Video provided by AFP
Powered by NewsLook.com
At Least 20 Chikungunya Cases in New Jersey

At Least 20 Chikungunya Cases in New Jersey

AP (July 30, 2014) At least 20 New Jersey residents have tested positive for chikungunya, a mosquito-borne virus that has spread through the Caribbean. (July 30) Video provided by AP
Powered by NewsLook.com
Generics Eat Into Pfizer's Sales

Generics Eat Into Pfizer's Sales

Reuters - Business Video Online (July 29, 2014) Pfizer, the world's largest drug maker, cut full-year revenue forecasts because generics could cut into sales of its anti-arthritis drug, Celebrex. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

    Environment News

    Technology News



      Save/Print:
      Share:

      Free Subscriptions


      Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

      Get Social & Mobile


      Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

      Have Feedback?


      Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
      Mobile: iPhone Android Web
      Follow: Facebook Twitter Google+
      Subscribe: RSS Feeds Email Newsletters
      Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins